» Articles » PMID: 38928448

Therapeutic Applications of Aptamers

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jun 27
PMID 38928448
Authors
Affiliations
Soon will be listed here.
Abstract

Affinity reagents, or target-binding molecules, are quite versatile and are major workhorses in molecular biology and medicine. Antibodies are the most famous and frequently used type and they have been used for a wide range of applications, including laboratory techniques, diagnostics, and therapeutics. However, antibodies are not the only available affinity reagents and they do have significant drawbacks, including laborious and costly production. Aptamers are one potential alternative that have a variety of unique advantages. They are single stranded DNA or RNA molecules that can be selected for binding to many targets including proteins, carbohydrates, and small molecules-for which antibodies typically have low affinity. There are also a variety of cost-effective methods for producing and modifying nucleic acids in vitro without cells, whereas antibodies typically require cells or even whole animals. While there are also significant drawbacks to using aptamers in therapeutic applications, including low in vivo stability, aptamers have had success in clinical trials for treating a variety of diseases and two aptamer-based drugs have gained FDA approval. Aptamer development is still ongoing, which could lead to additional applications of aptamer therapeutics, including antitoxins, and combinatorial approaches with nanoparticles and other nucleic acid therapeutics that could improve efficacy.

Citing Articles

Development and Characterization of CD44-Targeted X-Aptamers with Enhanced Binding Affinity for Cancer Therapeutics.

Wang H, He W, Elizondo-Riojas M, Zhou X, Lee T, Gorenstein D Bioengineering (Basel). 2025; 12(2).

PMID: 40001633 PMC: 11852163. DOI: 10.3390/bioengineering12020113.


Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner.

Ikeda R, Kimura C, Nihashi Y, Umezawa K, Shimosato T, Takaya T Life (Basel). 2025; 14(12.

PMID: 39768281 PMC: 11679607. DOI: 10.3390/life14121572.


Aptamer's Structure Optimization for Better Diagnosis and Treatment of Glial Tumors.

Koshmanova A, Artyushenko P, Shchugoreva I, Fedotovskaya V, Luzan N, Kolovskaya O Cancers (Basel). 2024; 16(23).

PMID: 39682297 PMC: 11640682. DOI: 10.3390/cancers16234111.


Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker.

Brylev V, Ryabukhina E, Nazarova E, Samoylenkova N, Gulyak E, Sapozhnikova K Pharmaceutics. 2024; 16(11).

PMID: 39598559 PMC: 11597439. DOI: 10.3390/pharmaceutics16111434.


Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review.

Shahbazlou S, Vandghanooni S, Dabirmanesh B, Eskandani M, Hasannia S Mikrochim Acta. 2024; 191(11):659.

PMID: 39382786 DOI: 10.1007/s00604-024-06740-3.

References
1.
Huygens S, Preijers T, Swaneveld F, Budde I, GeurtsvanKessel C, Koch B . Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study. Clin Pharmacokinet. 2024; 63(4):497-509. PMC: 11052786. DOI: 10.1007/s40262-024-01351-w. View

2.
Pieken W, Olsen D, Benseler F, Aurup H, Eckstein F . Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science. 1991; 253(5017):314-7. DOI: 10.1126/science.1857967. View

3.
Liu H, Gaza-Bulseco G, Sun J . Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 837(1-2):35-43. DOI: 10.1016/j.jchromb.2006.03.053. View

4.
Veedu R, Wengel J . Locked nucleic acid nucleoside triphosphates and polymerases: on the way towards evolution of LNA aptamers. Mol Biosyst. 2009; 5(8):787-92. DOI: 10.1039/b905513b. View

5.
Drolet D, Green L, Gold L, Janjic N . Fit for the Eye: Aptamers in Ocular Disorders. Nucleic Acid Ther. 2016; 26(3):127-46. PMC: 4900223. DOI: 10.1089/nat.2015.0573. View